<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556049</url>
  </required_header>
  <id_info>
    <org_study_id>07-212</org_study_id>
    <nct_id>NCT00556049</nct_id>
  </id_info>
  <brief_title>Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if the combination of sunitinib and
      gemcitabine is effective in treating patients with metastatic renal cell carcinoma. The
      safety of this combination will also be studied. Sunitinib is approved by the FDA for the
      treatment of renal cell carcinoma. However, some patients' cancers do not respond to
      treatment or stops responding after initially responding. Gemcitabine is a chemotherapy drug
      that is approved by the FDA for the treatment of pancreatic cancer and several other cancers.
      It is not approved for the treatment of renal cell carcinoma. Previous research has suggested
      that combining gemcitabine with sunitinib may have some effectiveness in treating metastatic
      renal cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will receive study treatment as an outpatient. Study treatment will be
           given in 3-week cycles.

        -  Sunitinib will be taken orally once per day for the first two weeks (days 1-14) of each
           treatment cycle.

        -  Gemcitabine will be given intravenously at the study clinic on days 1 and 8 of each
           treatment cycle.

        -  Before receiving sunitinib and gemcitabine on day 1 of each cycle the following will be
           performed: physical exam, performance status assessment and blood work. Before receiving
           gemcitabine on day 8 the following will be performed: physical exam, performance status
           assessment and blood work. Every 3 cycles a CT scan will be performed to measure the
           tumor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy.</measure>
    <time_frame>Until disease progression</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Neoplasm Metastases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib and gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenously on days 1 and 8 of each 21-day treatment cycle.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Orally on days 1-14 of each 21-day treatment cycle</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven metastatic renal cell carcinoma with any sarcomatoid histology
             or poor-risk features as defined by having 3 or more of the following characteristics:

               -  PS &gt; 1, high serum lactate dehydrogenase

               -  low hemoglobin

               -  high &quot;corrected&quot; serum calcium

               -  2 or more sites of metastatic disease

               -  time from initial diagnosis to evidence of metastatic disease 12 months or less

          -  Evidence of unidimensional measurable disease based on RECIST criteria, with at least
             1 measurable lesion

          -  Male or female, 18 years of age or older

          -  ECOG performance status of 0-2

          -  Patients with brain metastasis can only be included of they were treated 4 weeks or
             more prior to enrollment with whole brain radiation and the effects of treatment have
             resolved

          -  Resolution of all acute toxic effects of prior therapy, radiotherapy or surgical
             procedure to NCI CTCAE version 3.0 grade of 1 or less

          -  Laboratory values as outlined in the protocol

          -  2 weeks or more must have elapsed from the time of major surgery or radiation therapy
             prior to the day of registration

          -  No anticipated need for major surgical procedure during the course of the study

        Exclusion Criteria:

          -  Prior treatment with sunitinib or gemcitabine

          -  More than one prior systemic therapy of any kind for renal cell carcinoma

          -  Uncontrolled high blood pressure

          -  Any prior history of hypertensive crisis or hypertensive encephalopathy

          -  Any of the following within the 6 months prior to study drug administration:
             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
             graft, cerebrovascular accident or transient ischemic attack, or symptomatic
             congestive heart failure

          -  Ejection fraction &lt; 30%

          -  Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
             the normal range with medication

          -  NCT CTCAE grade 3 or higher hemorrhage within 4 weeks of starting treatment

          -  Significant vascular disease

          -  Current grade 3 or higher cardiac dysrhythmia or QT prolongation

          -  Concurrent use of proarrhythmic medications including terfenadine, quinidine,
             procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone,
             indapamide, and flecainide

          -  Pregnancy or breastfeeding or inadequate contraception

          -  Evidence of bleeding diathesis or coagulopathy

          -  Serious, non-healing wound, ulcer or bone fracture

          -  Psychiatric illness/social situation that would limit compliance with study
             requirements

          -  Previous diagnosis of concurrent malignancy requiring active systemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Dror Michaelson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center`</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2007</study_first_submitted>
  <study_first_submitted_qc>November 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <results_first_submitted>March 24, 2015</results_first_submitted>
  <results_first_submitted_qc>March 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 3, 2015</results_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Dror Michaelson, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>mRCC</keyword>
  <keyword>sunitinib</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Sunitinib and gemcitabine
Gemcitabine: Intravenously on days 1 and 8 of each 21-day treatment cycle.
Sunitinib: Orally on days 1-14 of each 21-day treatment cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Sunitinib and gemcitabine
Gemcitabine: Intravenously on days 1 and 8 of each 21-day treatment cycle.
Sunitinib: Orally on days 1-14 of each 21-day treatment cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="45" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy.</title>
        <time_frame>Until disease progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Sunitinib and gemcitabine
Gemcitabine: Intravenously on days 1 and 8 of each 21-day treatment cycle.
Sunitinib: Orally on days 1-14 of each 21-day treatment cycle</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy.</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Neutropenia</title>
          <description>Sunitinib and gemcitabine
Gemcitabine: Intravenously on days 1 and 8 of each 21-day treatment cycle.
Sunitinib: Orally on days 1-14 of each 21-day treatment cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. M. Dror Michaelson</name_or_title>
      <organization>MGH Cancer Center</organization>
      <phone>617-726-1594</phone>
      <email>dmichaelson1@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

